Insider buying
~$223K5,000 sh @ $44.56
Traded Nov 12 · filed 1 day later
Since the trade −3.1% · S&P 500 −8.9% · to Nov 20
Bought 20% below the 52-week high, RSI 42, 9% under its 200-day average, 12 points behind the S&P 500 over 3 months
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Checked for new insider filings 2 h ago
Guides: What is an SEC Form 4 · the transaction codes · who has to file · 10b5-1 plans
Worth a look: purchases of $10K+ and sales of $250K+ not reported under a pre-arranged trading plan.
Insider buying
Traded Nov 12 · filed 1 day later
Since the trade −3.1% · S&P 500 −8.9% · to Nov 20
Bought 20% below the 52-week high, RSI 42, 9% under its 200-day average, 12 points behind the S&P 500 over 3 months
Global Partners's Reporting person paid $223K out of pocket for Global Partners shares.
Lately at Global Partners LP: it reported its results on Nov 6; the stock is down 14% in 30 days; insiders made 11 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Insider buying
First insider buy since Sep 2025Traded Nov 10 · filed 3 days later
Since the trade −20.4% · S&P 500 −8.0% · to Nov 20
Bought within 3% of the 52-week high, RSI 61, 25% above its 200-day average
A Zai Lab director paid $33K out of pocket for Zai Lab shares. It was the first purchase in over a year.
Lately at Zai Lab: the stock rose 13% in one session on Nov 6 around a company release; it reported its results on Nov 5; the stock is down 13% in 30 days.
Insider selling
Traded Nov 13 · filed the same day
A Jfrog director told the SEC about a plan to sell $4.42M of Jfrog shares around Nov 13, 2026. The shares were not acquired as compensation. That is a tiny part of all Jfrog shares.
Lately at Jfrog: the stock rose 35% in one session on Nov 6 around a company release; it reported its results on Nov 5.
Traded Nov 11 – Nov 12, 2026 · largest single transaction ~$9.09MNot reported under a pre-arranged trading plan
Lately at Royal Caribbean Group: it reported its results on Oct 27; insiders made no purchase ($10K+) and 59 large sales ($250K+, not pre-arranged) in 90 days.
Nov 11, 2026~$9.09M · 27K sh @ $335.20
DetailsOfficial recordNov 11, 2026~$8.37M · 25K sh @ $337.37
DetailsOfficial recordNov 11, 2026~$7.86M · 23K sh @ $340.55
DetailsOfficial recordNov 11, 2026~$7.55M · 22K sh @ $339.65
DetailsInsider selling
11 days before an 8-KTraded Nov 9 · filed 4 days laterNot reported under a pre-arranged trading plan
Since the trade −32.5% · S&P 500 −8.3% · to Nov 20
An Enphase Energy director sold $8.73M of Enphase Energy shares. The filing does not indicate a pre-arranged trading plan.
Lately at Enphase Energy: the stock fell 16% in one session on Oct 28 around a company release; it announced job cuts, closures or a restructuring on Nov 20; the stock is down 39% in 30 days.
Insider selling
Traded Nov 13 · filed the same day
A Bbb Foods insider told the SEC about a plan to sell $4.08M of Bbb Foods shares around Nov 13, 2026. The shares were not acquired as compensation. That is a tiny part of all Bbb Foods shares.
Lately at Bbb Foods: the stock rose 11% in one session on Nov 3 with press coverage; the stock is up 11% in 30 days; insiders made no purchase ($10K+) and 2 large sales ($250K+, not pre-arranged) in 90 days.
Insider buying
5 days before an 8-KTraded Nov 11 · filed 2 days later
Since the trade +7.9% · S&P 500 −9.2% · to Nov 20
Bought 58% below the 52-week high, RSI 51, 21% under its 200-day average, 25 points behind the S&P 500 over 3 months
A major shareholder of Nextcure paid $63K out of pocket for Nextcure shares.
Lately at Nextcure: it received a notice from its stock exchange on Nov 20; the stock is up 19% in 30 days; insiders made 4 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 11 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade −7.6% · S&P 500 −9.2% · to Nov 20
The CFO of Roivant Sciences sold $3.45M of Roivant Sciences shares. The filing does not indicate a pre-arranged trading plan.
Lately at Roivant Sciences: it reported its results on Nov 9; the stock is up 5% in 30 days; insiders made no purchase ($10K+) and 22 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Their largest sale since 2014Traded Nov 12 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −1.9% · S&P 500 −8.9% · to Nov 20
The CEO of Hanover Insurance sold $2.59M of Hanover Insurance shares. The filing does not indicate a pre-arranged trading plan.
Lately at Hanover Insurance: it reported its results on Oct 28; insiders made no purchase ($10K+) and 5 large sales ($250K+, not pre-arranged) in 90 days.
Traded Nov 11 – Nov 12, 2026 · largest single transaction ~$6MNot reported under a pre-arranged trading plan
Lately at Ibotta: the stock rose 21% in one session on Nov 3 around a company release; it changed a top executive or board member on Nov 17; the stock is up 9% in 30 days.
Nov 11, 2026~$5.9M · 100K sh @ $58.97
DetailsOfficial recordNov 12, 2026~$6M · 100K sh @ $59.97
DetailsOfficial recordInsider selling
Traded Nov 12 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −0.7% · S&P 500 −8.9% · to Nov 20
A Globalstar director sold $7.77M of Globalstar shares. The filing does not indicate a pre-arranged trading plan.
Lately at Globalstar: it reported its results on Nov 5; insiders made no purchase ($10K+) and 4 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 10 · filed 3 days laterNot reported under a pre-arranged trading plan
Since the trade −11.5% · S&P 500 −8.0% · to Nov 20
The CFO of Tapestry sold $3.25M of Tapestry shares. The filing does not indicate a pre-arranged trading plan.
Lately at Tapestry, Inc.: it changed a top executive or board member on Nov 12; insiders made no purchase ($10K+) and 11 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Their largest sale since 2008Traded Nov 10 · filed 3 days laterNot reported under a pre-arranged trading plan
Since the trade −3.6% · S&P 500 −8.0% · to Nov 20
Genpact's Senior Vice President and CHRO sold $8.61M of Genpact shares. The filing does not indicate a pre-arranged trading plan.
Lately at Genpact: it reported its results on Nov 5; the stock is up 6% in 30 days; insiders made no purchase ($10K+) and 2 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 10 · filed 3 days laterNot reported under a pre-arranged trading plan
Since the trade −17.6% · S&P 500 −8.0% · to Nov 20
The CEO of 10x Genomics sold $1.95M of 10x Genomics shares. The filing does not indicate a pre-arranged trading plan.
Lately at 10x Genomics: it reported its results on Nov 5; the stock is down 31% in 30 days.
Insider selling
Traded Nov 11 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade −23.2% · S&P 500 −9.2% · to Nov 20
An AMD director sold $5.08M of AMD shares. The filing does not indicate a pre-arranged trading plan.
Lately at AMD: the stock fell 17% in one session on Nov 5 with press coverage; it changed its bylaws, charter or fiscal year on Nov 20; the stock is down 23% in 30 days.
Nov 12, 2026~$6.1M · 19K sh @ $322.30
DetailsOfficial record